tbuckley/cabot-search huggingface dataset:
DNA Polymerases Pol θ/Pol η Involved in Error-Prone DNA Repair Are Highly Expressed in Multiple Myeloma and Upregulated By DNA Damage
Authors: Masanobu Sunaga, Tsukasa Oda, Eiko Yamane, Rei Ishihara, Yuki Murakami, Saki Watanabe, Yuta Asao, Yuta Masuda, Hisashi Takei, Nobuhiko Kobayashi, Yohei Osaki, Gotoh Nanami, Tetsuhiro Kasamatsu, Hiromi Koiso, Makiko Takizawa, Hiroaki Shimizu, Takuma Ishizaki, Yoshiyuki Ogawa, Akihiko Yokohama, Norifumi Tsukamoto, Takayuki Saitoh, Hirokazu Murakami, Hiroshi Handa
Journal: Blood (2019)
Well played: the joy of outdoor freedom
Authors: Juliet Dobson
Journal: BMJ (2019)

Children play in Manchester in 1969, jumping in and out of burnt-out cars, balancing on a fallen tree, having fun. The image recalls a postwar era when children played freely outside, unrestricted by today’s health and safety concerns.

It was taken by Shirley Baker, a rare female photographer in Britain in the decades after the second world war. She was best known for …
A Novel Approach for Generating Platelet-Delivered FVIII: Role of Transient LRP1 Expression during Megakaryopoiesis
Authors: John Tkaczynski, Randolph Lyde, Hyunsook Ahn, Francis Ayombil, Sara Borst, Paul Gadue, Deborah L French, Denise Sabatino, Rodney M. Camire, Mortimer Poncz
Journal: Blood (2019)
Excellent Survival and Immune Reconstitution Following Matched/Mismatched Unrelated and Mismatched Related Transplantation in Adult Patients with Sickle Cell Disease: Updated Results from a Single Center Experience
Authors: Amer Assal, Diane George, Monica Bhatia, Divaya Bhutani, Christian Gordillo, Suzanne Lentzsch, Ran Reshef, Markus Y Mapara
Journal: Blood (2019)
Phase 1b/2 Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Analysis
Authors: Christopher Melani, Rahul Lakhotia, Stefania Pittaluga, Milos D. Miljkovic, James D. Phelan, Jagan R. Muppidi, Craig J. Thomas, Michele Ceribelli, Frances Anne Tosto, Craig A. Portell, Rafic J. Farah, Seung Tae Lee, Anna Marie Juanitez, Seth M. Steinberg, Elaine S. Jaffe, Mark Roschewski, Louis M. Staudt, Wyndham H. Wilson
Journal: Blood (2020)
Association of Anesthesia Care and Cognitive Outcomes in Survivors of Childhood Acute Lymphoblastic Leukemia
Authors: Sachi Ishida, Norifumi Kuratani
Journal: JAMA Oncology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
ACTR-12. PHASE 2 STUDY OF DIANHYDROGALACTITOL (VAL-083) IN PATIENTS WITH MGMT-UNMETHYLATED, BEVACIZUMAB-NAÏVE GLIOBLASTOMA IN THE RECURRENT AND ADJUVANT SETTING
Authors: Barbara O’Brien, Marta Penas-Prado, Carolos Kamiya, Shiao- Pei Weathers, Alfred Yung, Monica Loghin, Rebecca Harrison, Jeffrey Bacha, Dennis Brown, Gregory Johnson, John Langlands, Richard Schwartz, Sarath Kanekal, Lorena Lopez, John deGroot
Journal: Neuro-Oncology (2019)

Abstract Current standard-of-care for glioblastoma (GBM) includes surgery followed by concurrent therapy with radiation and temozolomide (TMZ) followed by adjuvant TMZ (days 1–5 every 28 days. Almost all GBM patients experience recurrent/progressive disease, with a median survival after recurrence of 3–9 months. Second-line treatment for recurrent GBM with bevacizumab (BEV) has not improved survival, and effective therapies for GBM are lacking. Unmethylated promoter for O6-methylguanine-DNA-methyltransferase (MGMT) is a validated biomarker for TMZ-resistance and is correlated with poor patient prognosis. VAL-083 is a bi-functional DNA-targeting agent which rapidly induces interstrand DNA cross-links at N7-guanine, induces double-strand breaks and acts independent of MGMT DNA repair. The current ongoing trial is a biomarker-driven Phase 2 study in MGMT-unmethylated BEV-naïve adult GBM. The primary objective of this study is to determine the effect of VAL-083 on median overall survival (mOS) for MGMT-unmethylated GBM patients compared to historical control. Secondary efficacy endpoints include progression-free survival (PFS), overall response rate (ORR), duration of response (DOR), and quality-of-life. Thirty-five (35) subjects with recurrent GBM have received 40 mg/m2/day VAL-083 on days 1, 2, 3 of a 21-day cycle as the starting dose. Myelosuppression is the most common adverse event and a higher potential for this toxicity correlated with those patients who received a higher number of cycles of prior TMZ maintenance therapy, (&gt;5 cycles vs. ≤5 cycles, p&lt; 0.05). To minimize the potential for hematological toxicity in rGBM, subsequent subjects initiated treatment at 30 mg/m2/d VAL-083 x 3 consecutive days every 21 days. In addition, since TMZ is of limited value in the MGMT-unmethylated setting, a second arm in newly diagnosed GBM has been included to explore whether substituting TMZ with VAL-083 offers clinical benefit and extends the time to recurrence. Enrollment, safety data and study updates will be presented at the meeting. Clinicaltrials.gov identifier: NCT02717962.
Case 39-2000
Authors: Carolyn L. Rochester, Richard L. Kradin
Journal: New England Journal of Medicine (2000)

Presentation of CaseA 47-year-old woman was admitted to the hospital because of bronchopulmonary disease.Six years before admission, pneumonia had developed, and asthma and chronic obstructive pulmonary disease had been diagnosed. Thereafter, the patient had pneumonia and sinusitis at least twice a year. Three years before admission, hypogammaglobulinemia was detected. Immune globulin was administered intravenously every 6 weeks, resulting in fewer bouts of pneumonia, until 14 months before admission, when the infusions were no longer approved by her insurer. The patient was able to climb stairs and to take 45-minute walks while taking prednisone (5 mg daily).Thirty-seven days . . .
Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib Show Expansion of T-Cell Clonotypes Composed of Antitumor Cytotoxic CD8+ T-Cells
Authors: Maria Joao Baptista, Sivasubramanian Baskar, Keyvan Keyvanfar, Erika M Gaglione, Inhye E Ahn, Adrian Wiestner, Clare Sun
Journal: Blood (2019)
Advancements in Treatment for Newly Diagnosed Frail and Elderly Myeloma Patients: A Systematic Review
Authors: Syed Maaz Abdullah, Tariq Iqtidar Sadiq Syed, Muhammad Salman Faisal, Awais Ijaz, Syeda Sabeeka Batool, Muhaddis Ejaz Ahmad, Muhammad Abdullah Yousaf, Saif Ur Rehman, Maaz Ahmed Yusufi, Sravanthi Kotapati, Maimoona Khan, Asma Waheed, Khadija Zia Zaidi, Sikander Abdullah, Faiz Anwer
Journal: Blood (2019)
Beneficial Effects of Sunlight May Account for the Correlation Between Serum Vitamin D Levels and Cardiovascular Health—Reply
Authors: Mahmoud Barbarawi, Owais Barbarawi, JoAnn E. Manson
Journal: JAMA Cardiology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
NIR‐II Fluorescence Endoscopy for Targeted Imaging of Colorectal Cancer
Authors: Yongkuan Suo, Fengxia Wu, Pengfei Xu, Hui Shi, Tingzhong Wang, Hongguang Liu, Zhen Cheng
Journal: Advanced Healthcare Materials (2019)

Endoscopy is a clinical gold standard to exam the interior of a hollow organ or body cavity. For the first of time, this study presents the design and construction of a fluorescent endoscopic system that harnesses the power of the second near-infrared window II (NIR-II) fluorescence imaging. An NIR-II fluorescent molecular probe, indocyanine green (ICG) conjugated bevacizumab (Bev-ICG) that targets vascular endothelial growth factor (VEGF), is successfully synthesized and evaluated along with the NIR-II endoscopy imaging system. Simultaneous NIR-II fluorescence and white-light (WL) imaging of VEGF is validated in an orthotopic rat colorectal cancer model. This NIR-II endoscopy system is a generalizable design, and it is compatible with the most of current clinic endoscopies. Similar hardware upgrades are expected to greatly promote the application of NIR-II fluorescent imaging in the clinic.
Retrospective Analysis of Gemcitabine and Oxaliplatin (GemOx)-Based Treatment in Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
Authors: Jake R. Schade, Charles Kim, Esther Drill, Annie Qiu, Connie Lee Batlevi, Philip Caron, Donald Steven Colbourn, Audrey Hamilton, Paul A. Hamlin, Steven M. Horwitz, Andrew M. Intlekofer, Erel Joffe, Gottfried R. von Keudell, Anita Kumar, Ariela Noy, Michelle Okwali, Colette Owens, M. Lia Palomba, Ildefonso Rodriguez-Rivera, Craig S. Sauter, Heiko Schoder, David J. Straus, Santosha Vardhana, Anas Younes, Andrew D. Zelenetz, Matthew J Matasar
Journal: Blood (2019)
PATH-49. CLINICAL UTILITY OF PLASMA CELL-FREE DNA IN ADULT PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA – A PILOT PROSPECTIVE STUDY
Authors: Stephen Bagley, Seyed Nabavizadeh, Jazmine Mays, Jacob Till, Stephanie Yee, Jeffrey Ware, Samantha Guiry, MacLean Nasrallah, Scott Levy, Whitney Sarchiapone, Jasmin Hussain, Timothy Prior, Andrew Cucciara, Zev Binder, Donald O’Rourke, Steven Brem, Arati Desai, Erica Carpenter
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND Liquid biopsy has been not been widely utilized in patients with glioblastoma (GBM) compared to other solid tumors. However, the clinical utility of plasma cell-free DNA (cfDNA) in GBM has not been assessed prospectively or at the time of initial diagnosis. METHODS We conducted a prospective cohort study of patients with newly diagnosed GBM. Whole blood was collected in Streck® tubes at baseline prior to initial surgical resection and longitudinally during the course of adjuvant chemoradiotherapy. Plasma cfDNA concentration (ng/mL) was quantified by qPCR for a 115 bp amplicon of the human ALU repeat element, correlated with radiographic tumor burden by volumetry at multiple time points using Spearman rank correlation, and assessed for its impact on progression-free (PFS) and overall survival (OS) by Cox regression. RESULTS Prior to initial resection, GBM patients (N=42) had higher plasma cfDNA concentration compared to age-matched healthy controls (N=42) (mean 13.43 vs. 6.70 ng/mL, p&lt; 0.001). Plasma cfDNA concentration was correlated with radiographic tumor burden on subjects’ first post-radiation MRI scan (r=0.77, p=0.003) and tended to rise prior to or concurrently with radiographic tumor progression. Pre-operative plasma cfDNA concentration above the mean (&gt;13.4 ng/mL) was associated with inferior PFS (median 4.9 vs. 9.5 months, p=0.038) and OS (median 8.9 vs. 14.8 months, p=0.078). The impact on PFS persisted after adjusting for age, extent of resection, performance status, MGMT promoter methylation, and IDH1/2 mutational status (HR 2.48, 95% CI 1.1–6.1, p=0.046). CONCLUSIONS Plasma cfDNA may be an effective prognostic tool and noninvasive surrogate of tumor burden in newly diagnosed GBM. Tumor tissue samples from our cohort have been subjected to targeted next generation sequencing (NGS), and baseline plasma samples have been sent to Guardant Health for NGS. Plasma NGS results and concordance with matched tissue NGS will be included at time of presentation.
Real Life Experience in Clinical Practice with Recombinant Coagulation FVIII-Fc Fusion Protein
Authors: Teresa Álvarez Roman, Elena Monzón Manzano, Ihosvany Fernandez-Bello, Mónica Martín, María Isabel Rivas Pollmar, Raul Justo Sanz, Sara García Barcenilla, Paula Acuña, Tamara Cebanu, Miguel A Canales, Nora Butta, Victor Jimenez-Yuste
Journal: Blood (2019)
French National Retrospective Cohort of Hairy-Cell Leukemias: Risk of Second Malignancies after 10 Years of Follow-up
Authors: Jérôme Paillassa, Edouard Cornet, Stephanie Noel, Cecile Tomowiak, Aline Schmidt, Stephane Lepretre, Sandrine Vaudaux, Jehan Dupuis, Alain Devidas, Joly Bertrand, Charlotte Petitditdier, Stéphanie Haiat, Clara Mariette, Catherine Thieblemont, Didier Decaudin, Bernard Drenou, Jean Claude Eisenmann, Mario Ojeda, Agnès Olivrie, Marie-Pierre Gourin, Olivier Lambotte, Olivier Hermine, Jean Michel Karsenti, Pierre Feugier, Willy Vaillant, Jean Gutnecht, Eric Lippert, Fabienne Huysman, Kamel Ghomari, Marouane Boubaya, Vincent Levy, Jérémie Riou, Gandhi Damaj, Mathilde Hunault, Xavier Troussard
Journal: Blood (2019)
NHEJ-Mediated Gene Editing, a Versatile Approach to Correct a Variety of Fanconi Anemia Genes in HSCs
Authors: Francisco J Roman-Rodriguez, Laura Ugalde, Lara A. Alvarez, Begoña Díez-Cabezas, Jordi Surrallés, Maria Jose Ramirez, Massimo Bogliolo, Helmut Hanenberg, Julian Sevilla, Sandra Rodriguez-Perales, Raul Torres-Ruiz, Juan A. Bueren, Paula Rio
Journal: Blood (2019)
EORTC SPECTA-AYA: A molecular profiling platform for adolescents and young adults with cancer in Europe
Authors: T. de Rojas, B. Kasper, W. Van der Graaf, S.M. Pfister, F. Bielle, T. Ribalta, P. Shenjere, M. Preusser, S. Fröhling, M. Morfouace, M.G. McCabe
Journal: Annals of Oncology (2019)
Epigenomic Determinants of Transcriptional Activity in ASXL1-Mutant Chronic Myelomonocytic Leukemia
Authors: Moritz Binder, Alexandre Gaspar Maia, Ryan M. Carr, Christopher Pin, Kurt Berger, Bonnie Alver, Keith Robertson, David Marks, Martin Fernandez-Zapico, Mrinal M Patnaik
Journal: Blood (2019)
PATH-36. MACHINE LEARNING TO DETECT GLIOMAS IN URINE-BASED LIQUID BIOPSY
Authors: Yotaro Kitano, Kosuke Aoki, Takao Yasui, Kazuya Motomura, Fumiharu Ohka, Kuniaki Tanahashi, Masaki Hirano, Tomohide Nishikawa, Hiroyuki Shimizu, Junya Yamaguchi, Sachi Maeda, Shintaro Yamazaki, Toshihiko Wakabayashi, Atsushi Natsume
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND Diffuse gliomas are the most common primary malignant brain tumors, whose overall prognosis is quite dismal. Tumor-cell-secreted extracellular vesicles (EVs) participate in physiological and pathological processes and have potential applications to diagnostics of malignant tumors including diffuse gliomas. Because urine is less invasive to collect, development of early diagnosis based on urine EVs is eagerly awaited. In this study, we captured urine EVs of patients with gliomas efficiently with the nanowire device and compared expression profile of microRNAs (miRNAs) within urine EVs with that of healthy donors to identify diagnostic accuracy by a machine learning algorithm. METHODS 62 patients with diffuse gliomas, including 27 glioblastoma and 35 lower grade gliomas, and 100 healthy donors were analyzed, along with orthotopic transplant mouse model. Urinary EVs were obtained with the nanowire device which could collect EVs more efficiently than the conventional ultracentrifugation method (Yasui et.al., Science Adv.2017). Machine learning methods were performed to select the miRNAs which could distinguish patients with gliomas from healthy control. RESULTS More than 2400 miRNAs were obtained from all urine samples. We identified miRNA panels that provided high diagnostic accuracy of diffuse gliomas (92.5%). There were 440 miRNAs whose expression increased by more than 1.5 fold (p&lt; 0.05) as compared to healthy donor samples (glioma-upregulated miRNAs), whereas the expression of 87 miRNAs decreased to less than 2/3-fold (p&lt; 0.05) (glioma-downregulated miRNAs). Mouse miRNAs which were homologous to glioma-upregulated and -downregulated miRNAs showed significantly high and low level expressions, respectively, in glioma mouse models as compared to normal control mice, confirming the reliability of urine miRNA-based diagnosis. Furthermore, some of these glioma-upregulated miRNAs has been reported to be involved in tumor progression. CONCLUSIONS miRNAs obtained from urine could be biomarkers for detection of gliomas by machine learning and some of these could be associated with tumor progression.
Pre-Transplant Fecal Microbial Diversity Independently Predicts Critical Illness after Hematopoietic Cell Transplantation
Authors: Fatima I. Adhi, Eric R. Littmann, Ying Taur, Molly A. Maloy, Kate A Markey, Emily Fontana, Luigi A Amoretti, Roberta Wright, Miriam Sanchez-Escamilla, Nerea Castillo Flores, Ana Alarcon Tomas, Richard J Lin, Lucrecia Yáñez, Daniel Brereton, Annelie Clurman, John B. Slingerland, Gunjan L. Shah, Christina Cho, Michael Scordo, Ioannis Politikos, Boglarka Gyurkocza, Doris M Ponce, Juliet Barker, Miguel-Angel Perales, Sergio A Giralt, Marcel R.M. van den Brink, Eric G. Pamer, Jonathan U. Peled
Journal: Blood (2019)
Allogeneic Anti-CD19 CAR T Cells Manufactured from Healthy Donors Provide a Unique Cellular Product with Distinct Phenotypic Characteristics Compared to CAR T Cells Generated from Patients with Mature B Cell Malignancies
Authors: Charlotte Graham, Agnieszka Jozwik, Ruby Quartey-Papafio, Nikolaos Ioannou, Ana M Metelo, Carlo Scala, Glenda Dickson, Orla Stewart, Maria Almena-Carrasco, Elisa Peranzoni, Alan G. Ramsay, Sandra Dupouy, Farzin Farzaneh, Piers E.M. Patten, Andrea Pepper, Reuben Benjamin
Journal: Blood (2019)
Clinical ALK5 Inhibitor, Vactosertib, Reverses TGFβ-1 Stimulated Smad-2 Driven Ineffective Hematopoiesis in MDS
Authors: Srinivas Aluri, Kimo Bachiashvili, Anjali Budhathoki, Tushar D Bhagat, Gaurav S Choudhary, Shanisha Gordon, Nandini Ramachandra, Kith Pradhan, Shahina Maqbool, Aditi Shastri, Jung Im Huh, Sunjin Hwang, Kim Seong-Jin, Hui Zhang, Britta Will, Amittha Wickrema, Ulrich G. Steidl, Amit Verma
Journal: Blood (2019)
Fecal Microbiota Transplantation As a Treatment of Severe Steroid-Resistant Acute and Chronic Graft Versus Host Disease. Spectrum of Responses and Complications
Authors: Jaroslaw Bilinski, Karol Lis, Agnieszka Tomaszewska, Pawel Grzesiowski, Aleksandra Pechcinska, Tomasz Dzieciatkowski, Kazimierz Halaburda, Magdalena Tormanowska, Martyna Tyszka, Krzysztof Mądry, Ewa Karakulska-Prystupiuk, Alicja Hoffman, Wieslaw W. Jedrzejczak, Grzegorz W Basak
Journal: Blood (2019)
Trends in prescription opioid use and dose trajectories before opioid use disorder or overdose in US adults from 2006 to 2016: A cross-sectional study
Authors: Yu-Jung Jenny Wei, Cheng Chen, Roger Fillingim, Siegfried O. Schmidt, Almut G. Winterstein
Journal: PLoS Medicine (2019)

Background With governments' increasing efforts to curb opioid prescription use and limit dose below the Centers for Disease Control and Prevention (CDC)-recommended threshold of 90 morphine milligram equivalents per day, little is known about prescription opioid patterns preceding opioid use disorder (OUD) or overdose. This study aimed to determine prescribed opioid fills and dose trajectories in the year before an incident OUD or overdose diagnosis using a 2005–2016 commercial healthcare database. Methods and findings This cross-sectional study identified individuals aged 18 to 64 years with incident OUD or overdose in the United States. We measured the prevalence of opioid prescription fills and trajectories of opioid morphine equivalent dose (MED) prescribed during the 12-month period before the diagnosis. Of 227,038 adults with incident OUD or overdose, 33.1% were aged 18 to 30 years, 52.9% were males, and 85.0% were metropolitan residents. Half (50.5%) of the patients had a diagnosis of chronic pain, 32.7% had depression, and 20.3% had anxiety. Overall, 79,747 (35.1%) patients filled no opioid prescription in the 12 months before OUD or overdose diagnosis, with the proportion significantly increasing between 2006 and 2016 (adjusted prevalence ratio, 1.86; 95% CI 1.79–1.93; P < 0.001). Patients without (versus with) prescribed opioids tended to be younger males and metropolitan and Northeast US residents. Of 145,609 patients who filled opioid prescriptions, 5 distinct prescribed daily dose trajectories preceding diagnosis emerged: consistent low dose (<3 mg MED, 34.6%), consistent moderate dose (20 mg MED, 27.3%), consistent high dose (150 mg MED, 15.0%), escalating dose (from <3 to 20 mg MED, 13.7%), and de-escalating dose (from 20 to <3mg MED, 9.4%). Overall, over two-thirds of patients with OUD or overdose with prescription opioids were prescribed a mean daily dose below 90 mg MED before diagnosis. Major limitations include the limited generalizability of the study findings and lack of information on out-of-pocket drug spending, race/ethnicity, and socioeconomic status of participants, which prevents analyses addressing these characteristics. Conclusions In this study, we found that absence of opioid prescription fills in the year before incident OUD or overdose diagnosis was prevalent, and the majority of the patients received prescription opioid doses below the risk threshold of 90 mg MED. An increasing proportion of high-risk patients could be missed by current programs solely based on opioid prescribing and dispensing information in this new era of limited access to prescription opioids.
Lisocabtagene Maraleucel (liso-cel) Manufacturing Process Control and Robustness across CD19+ Hematological Malignancies
Authors: Jeffrey Teoh, Timothy G. Johnstone, Brian Christin, Rachel Yost, Neil A. Haig, Mary Mallaney, Aditya Radhakrishnan, Heidi H. Gillenwater, Tina Albertson, Paul Guptill, Lauren F. Brown, Christopher G. Ramsborg, Ronald J. Hause, Ryan P. Larson
Journal: Blood (2019)
Response to Bcma CAR-T Cells Correlates with Pretreatment Target Antigen Density and Is Improved By Small Molecule Inhibition of Gamma Secretase
Authors: Damian J. Green, Margot Pont, Andrew J. Cowan, Gabriel O Cole, Blythe Duke Sather, Anne M Nagengast, Xaoling Song, Sushma Thomas, Brent L Wood, Michelle L Blake, Melissa G Works, Ted A Gooley, David G. Maloney, Stanley R. Riddell
Journal: Blood (2019)
Response to Erythropoiesis Stimulating Agents in Patients with WHO-Defined Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T)
Authors: Guadalupe Belen Antelo, Giacomo Coltro, Abhishek A Mangaonkar, Terra Lasho, Christy Finke, Ryan M. Carr, Naseema Gangat, Moritz Binder, Aref Al-Kali, Michelle A Elliott, Matthew T Howard, Rebecca L. King, William J Hogan, Mark Litzow, Animesh Pardanani, Ayalew Tefferi, Martin Fernandez-Zapico, Mrinal M Patnaik
Journal: Blood (2019)